(Q69548004)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

title

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

author name string

S A Rosenberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

M T Lotze

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

J C Yang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

P M Aebersold

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

W M Linehan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

C A Seipp

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

D E White

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

language of work or name

English

0 references

publication date

1 October 1989

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

volume

210

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

page(s)

474-84; discussion 484-5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

3 October 2019

cites work

1 reference

12 December 2020

Tumor necrosis factor: still a promising agent

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

12 December 2020

Lymphokine-activated killer cells: a new approach to immunotherapy of cancer

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma

1 reference

12 December 2020

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2

1 reference

12 December 2020

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

12 December 2020

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types

1 reference

12 December 2020

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

12 December 2020

Immune interventions in disease

1 reference

12 December 2020

Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy

1 reference

12 December 2020

Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials

1 reference

12 December 2020

Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors

1 reference

12 December 2020

Interleukin-2: inception, impact, and implications

1 reference

12 December 2020

Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

1 reference

12 December 2020

Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha

1 reference

12 December 2020

The development of new immunotherapies for the treatment of cancer using interleukin-2. A review

1 reference

12 December 2020

Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells

1 reference

12 December 2020

Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

1 reference

12 December 2020

Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells

1 reference

12 December 2020

Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.

1 reference

12 December 2020

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

12 December 2020

Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma

1 reference

12 December 2020

Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.

1 reference

12 December 2020

10.1097/00000658-198910000-00008

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2679456%20AND%20SRC:MED&resulttype=core&format=json

3 October 2019

0 references

1 reference